Anlon Healthcare Ltd

Preferential warrants approval

• Board approved a preferential issue of warrants convertible into equity up to Rs 250 crore.
• Warrants are fully convertible into equity shares with face value Rs 2 each.
• Issuance to promoters and public investors under SEBI ICDR regulations.
• Aggregate amount not exceeding Rs 250 crore.
• Investors named: two promoters and two public entities.
• Price and other specifics to be decided in the ensuing board meeting.
• Upfront payment 25%; balance 75% at allotment; 18-month exercise window; forfeiture on non-exercise.

Meeting Details

• Board meeting scheduled for October 13, 2026; time and venue not disclosed.

Key Agenda Items

• Discuss business expansion plans in India and overseas.
• Consider raising funds in tranches via equity, debt, or hybrids, subject to regulatory approvals.

Anlon Healthcare Limited: Closure of Trading Window from October 01, 2026 till the expiry of 48 hours after declaration of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2026

Participation details

• Company to participate virtually in Bharat Connect Conference Rising Stars 2026 on Sept 29, 2026, 3–4 PM IST.
• No UPSI will be shared at the meeting.

Filing Status

• ANLON HEALTHCARE NIGERIA LIMITED incorporated as subsidiary, effective 20 September 2026.
• Registration No. 9874492; turnover Nil as newly incorporated.

Ownership & Capital

• Anlon holds 90% of the subsidiary's share capital.
• Total equity subscription: Naira 90,000,000 for 90,000,000 shares.
• Authorized and paid-up capital of subsidiary: Naira 100,000,000.

Business Scope

• Manufacture, import, process, produce, trade, package APIs, bulk drugs, intermediates, finished dosage forms.
• Also cosmetics, personal care products, surgical implants and medical devices.
• Target 16 West African countries via local entity.

Timeline

• Incorporated on 20/09/2026.
• Regulatory approvals not required.

Share swap disclosures

• AGM held Sept 5, 2026; shareholders approved the proposed share swap.
• Share swap aims to acquire 44.94% in Apiqo Organics and 47.41% in Bizotic Lifescience.
• Floor price fixed at Rs 17.85 per share; price determined per SEBI ICDR rules.
• Valuation report dated Aug 6, 2026; revised Sept 1, 2026; fair value Rs 17.85.
• Pricing uses SEBI ICDR Regulation 164 framework; floor price via VWAP (90-day Rs 17.85; 10-day Rs 14.99).
• Identity of ultimate beneficial owners of proposed allottees disclosed; table lists 26+ entries.
• Certificate from M/s. K.P. Ghelani & Associates certifying ICDR compliance; hosted online.
• Disclosures form an integral part of AGM Notice read with Corrigendum.
• Second BSE/NSE observations were responded to; AGM disclosures remain unchanged otherwise.

Pricing basis

• Floor price fixed at Rs 17.85 per share under SEBI ICDR Regulation 164.
• Valuation report dated Sept 1, 2026 confirms fair value at Rs 17.85.
• Independent valuer CA Gaurang Agarwal issued the valuation report.
• Offer price is not less than the floor price per ICDR rules.

Ultimate beneficial owners

• Identities of ultimate beneficial owners for proposed allottees disclosed.
• List includes Unicorn Fund and other HUF entities; PAN details provided.
• PAN details of beneficiaries supplied for accountability.

Certification

• Certificate from M/s. K.P. Ghelani & Associates certifies ICDR-compliant preferential issue.

AGM and approvals

• AGM held on Sept 5, 2026; share swap approved by shareholders.
• Second BSE/NSE observations were addressed in disclosures.

Price movement clarification

• Affirms no undisclosed information exists and price movement is market-driven; all disclosures filed on time.